2024-04-012025-03-312025-03-31false13993382PRX PHARMACY LTD2025-10-30falseiso4217:GBPxbrli:pure139933822024-03-31139933822025-03-31139933822024-04-012025-03-31139933822023-03-31139933822024-03-31139933822023-04-012024-03-3113993382bus:SmallEntities2024-04-012025-03-3113993382bus:AuditExempt-NoAccountantsReport2024-04-012025-03-3113993382bus:FullAccounts2024-04-012025-03-3113993382bus:PrivateLimitedCompanyLtd2024-04-012025-03-3113993382core:WithinOneYear2025-03-3113993382core:AfterOneYear2025-03-3113993382core:WithinOneYear2024-03-3113993382core:AfterOneYear2024-03-3113993382core:ShareCapital2025-03-3113993382core:SharePremium2025-03-3113993382core:RevaluationReserve2025-03-3113993382core:OtherReservesSubtotal2025-03-3113993382core:RetainedEarningsAccumulatedLosses2025-03-3113993382core:ShareCapital2024-03-3113993382core:SharePremium2024-03-3113993382core:RevaluationReserve2024-03-3113993382core:OtherReservesSubtotal2024-03-3113993382core:RetainedEarningsAccumulatedLosses2024-03-3113993382core:LandBuildings2025-03-3113993382core:PlantMachinery2025-03-3113993382core:Vehicles2025-03-3113993382core:FurnitureFittings2025-03-3113993382core:OfficeEquipment2025-03-3113993382core:NetGoodwill2025-03-3113993382core:IntangibleAssetsOtherThanGoodwill2025-03-3113993382core:ListedExchangeTraded2025-03-3113993382core:UnlistedNon-exchangeTraded2025-03-3113993382core:LandBuildings2024-03-3113993382core:PlantMachinery2024-03-3113993382core:Vehicles2024-03-3113993382core:FurnitureFittings2024-03-3113993382core:OfficeEquipment2024-03-3113993382core:NetGoodwill2024-03-3113993382core:IntangibleAssetsOtherThanGoodwill2024-03-3113993382core:ListedExchangeTraded2024-03-3113993382core:UnlistedNon-exchangeTraded2024-03-3113993382core:LandBuildings2024-04-012025-03-3113993382core:PlantMachinery2024-04-012025-03-3113993382core:Vehicles2024-04-012025-03-3113993382core:FurnitureFittings2024-04-012025-03-3113993382core:OfficeEquipment2024-04-012025-03-3113993382core:NetGoodwill2024-04-012025-03-3113993382core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3113993382core:ListedExchangeTraded2024-04-012025-03-3113993382core:UnlistedNon-exchangeTraded2024-04-012025-03-3113993382core:MoreThanFiveYears2024-04-012025-03-3113993382core:Non-currentFinancialInstruments2025-03-3113993382core:Non-currentFinancialInstruments2024-03-3113993382dpl:CostSales2024-04-012025-03-3113993382dpl:DistributionCosts2024-04-012025-03-3113993382core:LandBuildings2024-04-012025-03-3113993382core:PlantMachinery2024-04-012025-03-3113993382core:Vehicles2024-04-012025-03-3113993382core:FurnitureFittings2024-04-012025-03-3113993382core:OfficeEquipment2024-04-012025-03-3113993382dpl:AdministrativeExpenses2024-04-012025-03-3113993382core:NetGoodwill2024-04-012025-03-3113993382core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3113993382dpl:GroupUndertakings2024-04-012025-03-3113993382dpl:ParticipatingInterests2024-04-012025-03-3113993382dpl:GroupUndertakingscore:ListedExchangeTraded2024-04-012025-03-3113993382core:ListedExchangeTraded2024-04-012025-03-3113993382dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-04-012025-03-3113993382core:UnlistedNon-exchangeTraded2024-04-012025-03-3113993382dpl:CostSales2023-04-012024-03-3113993382dpl:DistributionCosts2023-04-012024-03-3113993382core:LandBuildings2023-04-012024-03-3113993382core:PlantMachinery2023-04-012024-03-3113993382core:Vehicles2023-04-012024-03-3113993382core:FurnitureFittings2023-04-012024-03-3113993382core:OfficeEquipment2023-04-012024-03-3113993382dpl:AdministrativeExpenses2023-04-012024-03-3113993382core:NetGoodwill2023-04-012024-03-3113993382core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3113993382dpl:GroupUndertakings2023-04-012024-03-3113993382dpl:ParticipatingInterests2023-04-012024-03-3113993382dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-012024-03-3113993382core:ListedExchangeTraded2023-04-012024-03-3113993382dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-012024-03-3113993382core:UnlistedNon-exchangeTraded2023-04-012024-03-3113993382core:NetGoodwill2025-03-3113993382core:IntangibleAssetsOtherThanGoodwill2025-03-3113993382core:LandBuildings2025-03-3113993382core:PlantMachinery2025-03-3113993382core:Vehicles2025-03-3113993382core:FurnitureFittings2025-03-3113993382core:OfficeEquipment2025-03-3113993382core:AfterOneYear2025-03-3113993382core:WithinOneYear2025-03-3113993382core:ListedExchangeTraded2025-03-3113993382core:UnlistedNon-exchangeTraded2025-03-3113993382core:ShareCapital2025-03-3113993382core:SharePremium2025-03-3113993382core:RevaluationReserve2025-03-3113993382core:OtherReservesSubtotal2025-03-3113993382core:RetainedEarningsAccumulatedLosses2025-03-3113993382core:NetGoodwill2024-03-3113993382core:IntangibleAssetsOtherThanGoodwill2024-03-3113993382core:LandBuildings2024-03-3113993382core:PlantMachinery2024-03-3113993382core:Vehicles2024-03-3113993382core:FurnitureFittings2024-03-3113993382core:OfficeEquipment2024-03-3113993382core:AfterOneYear2024-03-3113993382core:WithinOneYear2024-03-3113993382core:ListedExchangeTraded2024-03-3113993382core:UnlistedNon-exchangeTraded2024-03-3113993382core:ShareCapital2024-03-3113993382core:SharePremium2024-03-3113993382core:RevaluationReserve2024-03-3113993382core:OtherReservesSubtotal2024-03-3113993382core:RetainedEarningsAccumulatedLosses2024-03-3113993382core:NetGoodwill2023-03-3113993382core:IntangibleAssetsOtherThanGoodwill2023-03-3113993382core:LandBuildings2023-03-3113993382core:PlantMachinery2023-03-3113993382core:Vehicles2023-03-3113993382core:FurnitureFittings2023-03-3113993382core:OfficeEquipment2023-03-3113993382core:AfterOneYear2023-03-3113993382core:WithinOneYear2023-03-3113993382core:ListedExchangeTraded2023-03-3113993382core:UnlistedNon-exchangeTraded2023-03-3113993382core:ShareCapital2023-03-3113993382core:SharePremium2023-03-3113993382core:RevaluationReserve2023-03-3113993382core:OtherReservesSubtotal2023-03-3113993382core:RetainedEarningsAccumulatedLosses2023-03-3113993382core:AfterOneYear2024-04-012025-03-3113993382core:WithinOneYear2024-04-012025-03-3113993382core:Non-currentFinancialInstrumentscore:CostValuation2024-04-012025-03-3113993382core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-04-012025-03-3113993382core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-04-012025-03-3113993382core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-04-012025-03-3113993382core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-04-012025-03-3113993382core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-04-012025-03-3113993382core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3113993382core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3113993382core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3113993382core:Non-currentFinancialInstrumentscore:CostValuation2025-03-3113993382core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-03-3113993382core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-03-3113993382core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-03-3113993382core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-03-3113993382core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-03-3113993382core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-03-3113993382core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-03-3113993382core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-03-3113993382core:Non-currentFinancialInstrumentscore:CostValuation2024-03-3113993382core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-3113993382core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-3113993382core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-3113993382core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-3113993382core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-3113993382core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-3113993382core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-3113993382core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-3113993382bus:Director12024-04-012025-03-3113993382bus:Director22024-04-012025-03-3113993382core:FurnitureFittingsToolsEquipment2024-03-3113993382core:FurnitureFittingsToolsEquipment2024-04-012025-03-3113993382core:FurnitureFittingsToolsEquipment2025-03-31

PRX PHARMACY LTD

Registered Number
13993382
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2025

PRX PHARMACY LTD
Company Information
for the year from 1 April 2024 to 31 March 2025

Directors

PATEL, Mayurikabahen Milan
PATEL, Milan

Registered Address

2nd Floor Grove House
55 Lowlands Road
Harrow
HA1 3AW

Registered Number

13993382 (England and Wales)
PRX PHARMACY LTD
Balance Sheet as at
31 March 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Intangible assets3634,919710,073
Tangible assets425,01324,957
659,932735,030
Current assets
Stocks582,42480,000
Debtors6366,890197,900
Cash at bank and on hand146,6795,856
595,993283,756
Creditors amounts falling due within one year7(785,152)(600,091)
Net current assets (liabilities)(189,159)(316,335)
Total assets less current liabilities470,773418,695
Creditors amounts falling due after one year8(457,459)(438,071)
Net assets13,314(19,376)
Capital and reserves
Called up share capital100100
Profit and loss account13,214(19,476)
Shareholders' funds13,314(19,376)
The financial statements were approved and authorised for issue by the Board of Directors on 30 October 2025, and are signed on its behalf by:
PATEL, Milan
Director
Registered Company No. 13993382
PRX PHARMACY LTD
Notes to the Financial Statements
for the year ended 31 March 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Intangible assets
Goodwill arising on acquisitions, represents any excess of the Fair value of the consideration given over the fair value of the identifiable assets acquired. Goodwill is initially recognised at cost. After initial recognition, they are measured at cost less any accumulated amortization and any accumulated impairment losses. Goodwill are are being amortized evenly over their estimated useful life of 10 years.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Land and buildings5
Fixtures and fittings5
Office Equipment5
Stocks and work in progress
Stocks are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Basic financial assets Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised. Basic financial liabilities Basic financial liabilities, including creditors are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
2.Average number of employees

20252024
Average number of employees during the year116
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 April 24751,537751,537
At 31 March 25751,537751,537
Amortisation and impairment
At 01 April 2441,46441,464
Charge for year75,15475,154
At 31 March 25116,618116,618
Net book value
At 31 March 25634,919634,919
At 31 March 24710,073710,073
4.Tangible fixed assets

Land & buildings

Fixtures & fittings

Office Equipment

Total

££££
Cost or valuation
At 01 April 249,83314,2922,33026,455
Additions--5,7865,786
At 31 March 259,83314,2928,11632,241
Depreciation and impairment
At 01 April 24968530-1,498
Charge for year1,9672,7521,0115,730
At 31 March 252,9353,2821,0117,228
Net book value
At 31 March 256,89811,0107,10525,013
At 31 March 248,86513,7622,33024,957
5.Stocks

2025

2024

££
Raw materials and consumables82,42480,000
Total82,42480,000
6.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables309,135165,319
Other debtors29,95728,789
Prepayments and accrued income27,7983,792
Total366,890197,900
7.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables88,70095,516
Bank borrowings and overdrafts19,58958,565
Taxation and social security44,39810,741
Other creditors632,465431,540
Accrued liabilities and deferred income-3,729
Total785,152600,091
8.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts457,459438,071
Total457,459438,071
Included within creditors falling due within one year and creditors falling due after more than one year is £477,048 (2024: £496,636) in respect of a loan from Unity bank. This loan is secured by a fixed and floating charge over present and future assets of the company.
9.Other commitments
LEASING AGREEMENTS: Minimum lease payments under non-cancellable operating leases fall due as follows: Due within one year: £71,500 (2024: 71,500)
10.Related party transactions
Included in other creditors falling due within one year is an amount of £201,093 (2024: £358,930) due to the director, Mr M Patel.